LYRA News and Press, Lyra Therapeutics Inc. From 07/12/21

WATERTOWN, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages...

Lyra Therapeutics (LYRA) perks up 8.3% premarket after announcing positive topline results from the pharmacokinetic ((PK)) study of LYR-210 in adults with chronic rhinosinusitis ((CRS)), an inflammatory disease of the paranasal sinuses.The study enrolled 24 patients, half of wh...

-- Results Support 505(b)(2) NDA Pathway for LYR-210 -- First U.S. Study of LYR-210 Enrolled Rapidly WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo!...

Aethlon Medical (AEMD) +280% after publication of its case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier®.Checkpoint Therapeutics (CKPT) +50%.Antelope Enterprise Holdings Limited (AEHL) +45%.SPI Energy (SPI) +41% as its group Company is build...

Single primary endpoint defined as three cardinal symptoms at 24 weeks Company to host conference call at 5:00 PM ET today Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to ...

Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Stemirna Therapeutics raised nearly $200 million to finance clinical trials and production of its messenger RNA COVID-19 vaccine candidate. ...

BriaCell Therapeutics (BCTX) +102% after update on the overall survival data of advanced breast cancer patients.Constellation Pharmaceuticals (CNST) +67% on merger agreement with MorphoSys.Stealth BioTherapeutics (MITO) +46% on EMA orphan drug status for elamipretide.AC Immune ...

Partnership opens expanded opportunity for LYR-210 to address chronic rhinosinusitis, a disease affecting approximately 88 million adults in China Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform ...

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Pal...

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Pal...